Back to Journals » ClinicoEconomics and Outcomes Research » Volume 10

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

Total article views   HTML views PDF downloads Totals
13,893 Dovepress* 10,487+ 1,615 12,102
PubMed Central* 3,406 768 4,174
Totals 13,893 2,383 16,276
*Since 14 November 2018
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar